Lantern Pharma receives rare paediatric disease and orphan drug designations for LP-184 for the treatment of atypical teratoid rhabdoid tumour

Lantern Pharma

24 January 2022 - Lantern Pharma today announced that the U.S. FDA has granted both rare paediatric disease designation and orphan drug designation for the company's drug candidate LP-184 for the treatment of paediatric patients with ATRT. 

LP-184 is being pursued as a potential new therapy across a range of genetically defined solid tumours, including pancreatic cancer, GBM (Glioblastoma Multiforme) and ATRT (Atypical Teratoid Rhabdoid Tumor).

Read Lantern Pharma press release

Michael Wonder

Posted by:

Michael Wonder